Prvi put u istoriji, lek u čijem otkriću je učestvovao Univerzitet u Beogradu – Farmaceutski fakultet dobio je odobrenje od strane američke Uprave za hranu i lekove da započne kliničko ispitivanje

DPX-101, pozitivni alosterni modulator koji selektivno deluje preko α5-GABA-A podtipareceptora, jedno je od jedinjenja čiji je ko-inventor dr Miroslav Savić (https://www.pharmacy.bg.ac.rs/nims/389/patenti/), redovni profesor na Katedri za farmakologiju Farmaceutskog fakulteta (Farmaceutski fakultet - Dr sc. Miroslav Savić). Kompanija Damona Pharmaceuticals, kao nosilac licencnih prava za ovo jedinjenje, dobila je od strane američke Uprave za hranu i lekovе odobrenje za sprovođenje kliničkih ispitivanja (FDA IND clearance), i prva faza kliničkog ispitivanja počinje pre kraja 2024. godine. DPX-101 se nalazi u kliničkom razvoju za terapiju kognitivnih deficita povezanih sa moždanim poremećajima, a puna informacija je dostupna na: https://www.damonapharma.com/damona-pharmaceuticals-announces-fda-clearance-of-ind-application-for-a-phase-1-clinical-trial-of-dpx-101-a-positive-allosteric-modulator-targeting-the-%ce%b15-gaba-a-receptor-subtype-selectively-wi/

For the first time, a drug co-invented at University of Belgrade – Faculty of Pharmacy approved by FDA to begin clinical trials

DPX-101, a positive allosteric modulator selectively targeting the α5-GABA-A receptor subtype, is one of compounds co-invented by Dr Miroslav Savić (https://www.pharmacy.bg.ac.rs/nims/389/patenti/), full professor at the Department of Pharmacology of Faculty of Pharmacy (https://www.pharmacy.bg.ac.rs/en/about-us/full-professors/640/miroslav-savic-phd/). Damona Pharmaceuticals, as the licensee of this ligand, has received the FDA clearance of the DPX-101 IND, and initiation of the Phase 1 clinical trial is planned for the end of 2024. DPX-101 is in clinical development for the treatment of cognitive deficits associated with brain disorders, and the full information is available at:https://www.damonapharma.com/damona-pharmaceuticals-announces-fda-clearance-of-ind-application-for-a-phase-1-clinical-trial-of-dpx-101-a-positive-allosteric-modulator-targeting-the-%ce%b15-gaba-a-receptor-subtype-selectively-wi/